October 25, 2014 5:02 AM ET

Biotechnology

Company Overview of Iconic Therapeutics, Inc.

Company Overview

Iconic Therapeutics, Inc., a biopharmaceutical company, develops production and purification procedures for proteins that attack and destroy pathologic cells. It develops hI-con1, a recombinant protein that triggers immune cell-mediated killing of TF-expressing uterine serous papillary adenocarcinoma and clear cell ovarian cancer cells. The company was incorporated in 2002 and is based in Atlanta, Georgia.

127 Peachtree Street, N.E.

Suite 1551

Atlanta, GA 30303

United States

Founded in 2002

Phone:

404-522-8577

Fax:

404-522-6366

Key Executives for Iconic Therapeutics, Inc.

Chief Executive Officer
Co-Founder
Chief Scientist and Scientific Advisor
Clinical Trials Advisor
Age: 52
Compensation as of Fiscal Year 2014.

Iconic Therapeutics, Inc. Key Developments

Iconic Therapeutics, Inc. Announces Management Appointments

Iconic Therapeutics, Inc. announced that MPM partner William Greene, MD, has joined the company as Chief Executive Officer. Additionally, MPM Managing Director Todd Foley, H.I.G. Managing Director Bruce Robertson, PhD, and Lundbeckfond Ventures Senior Partner Johan Kordel, PhD, have joined the Board of Directors. Prior to joining Iconic Therapeutics, Dr. Greene was a Managing Director at MPM Capital. Previously, he was a Senior Clinical Scientist at Genentech where he led the early clinical development of Lucentis for AMD.

Iconic Therapeutics, Inc. Announces Phase 1 Wet AMD Study Results

Iconic Therapeutics, Inc. announced that Dr. Christine Gonzales will present the results of its recently completed Phase 1 study of hI-con1 in wet adult macular degeneration (wet AMD) patients at the American Academy of Ophthalmology Retina Subspecialty Day on November 10, 2012 in Chicago. The purpose of the Phase 1 study was to evaluate the safety and tolerability of hI-con1 in wet AMD patients. The prospective, multi-center clinical study evaluated the safety and tolerability of a single, intravitreal injection of three different doses of hI-con1 in a total of 18 patients. hI-con1 was very well tolerated by all patients: no ocular or systemic safety signals were observed at any dose. A single injection of hI-con1 produced no dose limiting toxicities when used alone or when used with bevacizumab or ranibizumab. Notably, there were clear indications of dose-related, biologic activity in a number of patients, as indicated by increased visual acuity, reduced retinal thickness and CNV regression. Evidence of hI-con1 biological activity was observed both in previously untreated patients as well as patients not previously responding well to bevacizumab or ranibizumab (so-called sub-responders).

Similar Private Companies By Industry

Company Name Region
Abiomed R&D, Inc. United States
Calcigen Corporation United States
Amazon Biotech, Inc. United States
Gen-Probe Prodesse, Inc. United States
ARx, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 14, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Iconic Therapeutics, Inc., please visit www.iconictherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.